Navigation Links
Reliance Pharmaceuticals: Biosimilars Company Analysis

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- announces that a new market research report is available in its catalogue:


Reliance Pharmaceuticals: Biosimilars Company Analysis


This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.Reliance Life Sciences has a primary focus on biopharmaceuticals and pharmaceuticals, but also a presence in the wider areas of clinical research services, regenerative medicine, molecular medicine, and biofuels. The overall sales of Reliance Life Sciences totaled $104.7m in FY2011, with approximately 70% coming from biopharmaceutical products.Assess Reliance's portfolio of 7 marketed biosimilars and 20 pipeline products, which includes 3 monoclonal antibody productsSee how the 2007 acquisition of GeneMedix will help diversify Reliance's geographical focus




ABOUT THIS REPORT•Chapter structure - Strategic insight

- Product analysis

- Corporate structure


•Data sourcing

•PharmaVitae Explorer database


EXECUTIVE SUMMARY•Reliance Life Sciences biosimilars overview

•Reliance Life Sciences biosimilars infrastructure


STRATEGIC INSIGHT•Reliance Life Sciences made the strategic acquisition of GeneMedix to penetrate the European markets

•Reliance is focusing on the oncology therapy area and developing a portfolio of MAb biosimilars - Oncology focus


•Reliance Life Sciences biosimilars SWOT analysis - Strengths

- Weaknesses

- Opportunities

- Threats



KEY PRODUCTS•Reliance Life Sciences biosimilars portfolio

•ReliPoietin (epoetin alfa) - Overview

- Erythropoietin market size

- Key competitors


•ReliGrast (filgrastim)Reliance Life Sciences launched biosimilar granulocyte colony-stimulating factor (GCSF) ReliGrast in 2008. It is currently marketed in India and other semi-regulated markets. - Filgrastim and pegfilgrastim market size

- Key competitors


•ReliFeron (interferon alfa-2b) - Overview

- Interferon alfa market size

- Key competitors


•FostiRel (follitropin beta) - Market overview

- Key competitors


•ReliBeta (interferon beta-1a) - Overview

- Interferon beta market size

- Key competitors

- Reliance Life Sciences' other marketed products and biosimilar development




•Key corporate developments

•Company structure - Biopharmaceuticals

- Novel therapeutics

- Pharmaceuticals

- Clinical research services

- Regenerative medicine

- Molecular medicine

- Plant biotechnology

- Industrial biotechnology


•Deals and alliances

•Recent developments


APPENDIX•References - Datamonitor reports


•Exchange rates




•Table: Reliance Life Sciences biosimilars development and marketing capabilities

•Table: Forecast global sales of infliximab, rituximab, and abciximab ($m), 2011–16

•Table: Reliance Life Sciences – life sciences initiatives

•Table: Reliance Life Sciences – biosimilar/copy-biologic portfolio

•Table: Forecast epoetin sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic epoetin and darbepoetin drugs

•Table: Forecast filgrastim and pegfilgrastim sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic filgrastim and pegfilgrastim drugs

•Table: Forecast interferon alfa and peginterferon alfa sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic interferon alfa

•Table: Forecast follitropin alfa and beta sales in the seven major markets ($m), 2011–16

•Table: Biosimilar/copy-biologic follitropin drugs, 2012

•Table: Forecast interferon beta sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic interferon beta drugs

•Table: Reliance Life Sciences – monoclonal antibodies under development

•Table: Reliance Life Sciences/GeneMedix deal activity and biosimilar deals, 2000?12

•Table: Exchange rates, 2012




•Figure: The PharmaVitae Explorer

•Figure: Reliance Life Sciences biosimilars overview

•Figure: Mutual benefits through Reliance Life Sciences' acquisition of GeneMedix

•Figure: Reliance Life Sciences – biosimilar and pharmaceutical products and therapy area

•Figure: Reliance Life Sciences SWOT analysis

•Figure: Proportion of government and private health expenditure versus personal disposable income, in India and other major markets, 2009

•Figure: Reliance Life Sciences – revenues, FY2010–12

•Figure: Reliance Life Sciences – revenues, FY2010?12

•Figure: Reliance Life Sciences – company structure




Companies Mentioned

Antares Pharma, Inc., Asian Development Bank, CJ Corporation, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Merck KGaA, Reliance Industries Limited, Schindler Holding Ltd.




To order this report:

Biopharmaceutical Industry: Reliance Pharmaceuticals: Biosimilars Company Analysis


Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626


SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceuticals: Global Industry Almanac, MarketLine
2. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
3. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
6. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
7. Donor Alliance Named Colorados Top Healthcare Company
8. Aoxing Pharmaceutical Company, Inc. Declines To Comment On Market Activity
9. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
10. Elbit Imaging Ltd. Announces Standard & Poors Maalot Changes Rating of Companys Notes
11. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
(Date:10/13/2015)... Calif. , Oct. 13, 2015  SRI ... up to $100 million over five years by ... (NIAID), part of the National Institutes of Health, ... treat acute or delayed effects of radiation exposure. ... a division of SRI International will provide services, ...
(Date:10/13/2015)... , Oct. 13 2015 ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ... announced the addition of the "US ... - 16 Countries (2010-2021)" report to ...
(Date:10/13/2015)... 13, 2015 anesthesia and respiratory ... billion by 2022, according to a new report by ... to their capability to resolve various environmental and lifestyle ... growth. --> anesthesia and respiratory devices market ... 2022, according to a new report by Grand View ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... ... Scientists in Seattle and Vancouver compared the diagnostic value of lung fluid cytology ... has just posted an article on the new research. Click here to read ... of British Columbia found that certain genetic alterations were seen just as often in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Tempe Dental Care, a leading Tempe ... and IV sedation dentistry for more than 5 years. A leading cause ... serious and painful if treatment is not timely. , Sedation dentistry ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Local Gold’s ... Gold’s Gym International Conference on August 26. Berry, who owns and operates Gold's ... for the fastest growing Gold’s Gyms in the United States. A brand leader in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Thermi, an ... newest professional to introduce the latest development, ThermiVa® temperature controlled radiofrequency to the ... professional in Obstetrics and Gynecology and a pioneer in the field of laparoscopy. ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an ongoing effort ... , a Southlake, Texas, child development and pediatric therapy center, is working with ... families about their options for receiving this kind of care for affected children. ...
Breaking Medicine News(10 mins):